Monkeypox Stocks to Watch: SIGA Technologies Inc. (SIGA) SIGA Technologies (NASDAQ:SIGA) produces the Tecovirimat SIGA, or TPOXX smallpox vaccine as it’s known in the U.S., SIGA’s vaccine was approved in the United States for the treatment of smallpox in July 2018, and it received European approvals for the treatment of Smallpox, Monkeypox and Cowpox in January 2022. Following a Monkeypox rally that saw SIGA stock price skyrocket between the first of May and May 27, shares are in consolidation mode after a 13% decline since May 27. Investors speculate on the company’s economic benefits from a potential Monkeypox outbreak, and any new vaccine orders could reignite the speculative rally this month. Although it has been profitable historically, SIGA has a significantly volatile revenue history. That said, given its good working capital position, no debt in its capital structure and a positive free cash flow generation profile, SIGA stock could outperform if Monkeypox becomes a significant cause for concern enough for governments to increase orders for Tecovirimat and TPOXX.
Grill stock offers 4.75% yield? Tredegar Corporation (TG) NYSE - Nasdaq Real Time Price. 10.31+0.21 (+2.08%) As of 03:42PM EDT.
What an interesting move! Tredegar's (NYSE:TG) Dividend Will Be US$0.12 TG +2.08% Tredegar Corporation's (NYSE:TG) investors are due to receive a payment of US$0.12 per share on 1st of July. The dividend yield will be 3.8% based on this payment which is still above the industry average. Tredegar's Dividend Is Well Covered By Earnings A big dividend yield for a few years doesn't mean much if it can't be sustained. Based on the last payment, Tredegar was earning enough to cover the dividend, but free cash flows weren't positive. We think that cash flows should take priority over earnings, so this is definitely a worry for the dividend going forward. If the trend of the last few years continues, EPS will grow by 24.9% over the next 12 months. Assuming the dividend continues along recent trends, we think the payout ratio could be 20% by next year, which is in a pretty sustainable range.
New 52 week high Stoney. You were supposed to look into this. You don't find long term winners on SA's morning homepage. That's for the WSB's folks. I give you a great stock no one has ever heard of... and you're chasing bs penny stocks.
Well Stoney, a month later and the nasdaq is pretty much where it was, META is down almost 14%. About 59% from its highs. Hmmm. Ok, now it's safe to put some in the IRA. Slowly. I don't think the bottom's in yet though, but at PEG of about 1, a small add might be reasonable. META-->>> $155.85
The FDA ruling against Juul is seen as a positive for Philip Morris International (NYSE:PM), which may have the opportunity to enhance IQOS growth with Juul off the market. Philip Morris is noted to have approval for the IQOS HNB device and an application for its e-cigarette VEEV. British American Tobacco (BTI) is also seen as a key beneficiary if JUUL's products are removed from the market. BAT is anticipated to further consolidate its leadership position in U.S. e-cigarettes. BTI-$42 <---------------